Referenceprogram for unipolar depression hos voksne
Referenceprogram for unipolar depression hos voksne
Referenceprogram for unipolar depression hos voksne
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
300. Creed F, Mbaya P, Lancashire S, Tomenson B, Williams B, Holme S. Cost effectiveness of day<br />
and inpatient psychiatric treatment: Results of a randomised controlled trial. BMJ. 1997;314:1381-<br />
1385.<br />
301. Psykiatriens Kerneopgaver Og Ud<strong>for</strong>dringer 2004-2010. Dansk Psykiatrisk Selskab; 2004.<br />
302. Specialisering Og Faglig Bæredygtighed Inden <strong>for</strong> Psykiatrien. København: Danske Regioner; 2006.<br />
303. Drummond MF. Methods <strong>for</strong> the Economic Evaluation of Health Care Programmes. Vol 2. ed.,<br />
reprint. Ox<strong>for</strong>d: Ox<strong>for</strong>d University Press; 1997.<br />
304. Alban A. Sundhedsøkonomi. Principper Og Perspektiver. København: DSI. Institut <strong>for</strong><br />
Sundhedsvæsen; 1999.<br />
305. Kaplan W, Laing R. Priority medicines <strong>for</strong> europe and the world. WHO; 2004:1-154.<br />
306. Olesen J, Leonardi M. The burden of brain diseases in europe. Eur J Neurol. 2003;10:471-477.<br />
307. Lothgren M. Economic evidence in affective disorders: A review. Eur J Health Econ. 2004;5 Suppl<br />
1:S12-20.<br />
308. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in europe.<br />
Eur J Neurol. 2005;12 Suppl 1:1-27.<br />
309. Norinder A, Nordling S, Haggstrom L. Treatment of <strong>depression</strong> and cost efficiency. the cost of<br />
a tablet is a poor indicator seen from a socioeconomic perspective. Lakartidningen. 2000;97:1693-8,<br />
1700.<br />
310. von Knorring L, Akerblad AC, Bengtsson F, Carlsson A, Ekselius L. Cost of <strong>depression</strong>: Effect of<br />
adherence and treatment response. Eur Psychiatry. 2006;21:349-354.<br />
311. Russell JM, Hawkins K, Ozminkowski RJ, Orsini L, Crown WH, Kennedy S, Finkelstein<br />
S, Berndt E, Rush AJ. The cost consequences of treatment-resistant <strong>depression</strong>. J Clin Psychiatry.<br />
2004;65:341-347.<br />
312. Barrett B, By<strong>for</strong>d S, Knapp M. Evidence of cost-effective treatments <strong>for</strong> <strong>depression</strong>: A systematic<br />
review. J Affect Disord. 2005;84:1-13.<br />
313. Sorensen J, Stage KB, Damsbo N, Le Lay A, Hemels ME. A danish cost-effectiveness model<br />
of escitalopram in comparison with citalopram and venlafaxine as first-line treatments <strong>for</strong> major<br />
depressive disorder in primary care. Nord J Psychiatry. 2007;61:100-108.<br />
314. By<strong>for</strong>d S, Bower P. Cost-effectiveness of cognitive–behavioral therapy <strong>for</strong> <strong>depression</strong>: Current<br />
evidence and future research priorities. Expert Review of Pharmacoeconomics & Outcomes Research.<br />
2002;2:457-465.<br />
315. Guthrie E, Moorey J, Margison F, Barker H, Palmer S, McGrath G, Tomenson B, Creed F. Costeffectiveness<br />
of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services. Arch<br />
Gen Psychiatry. 1999;56:519-526.<br />
<strong>Referenceprogram</strong> <strong>for</strong> <strong>unipolar</strong> <strong>depression</strong> <strong>hos</strong> <strong>voksne</strong> 123
Change language